【摘要】：2型糖尿病表現(xiàn)為糖脂代謝紊亂并伴隨多臟器慢性損害,已成為威脅人類健康的巨大隱患。α/β水解酶結(jié)構(gòu)域-6(α/βhydrolase domain-6,ABHD6)通過水解單酰甘油,負調(diào)控胰島素的釋放。小分子ABHD6抑制劑因其在增強胰島素敏感性、改善脂肪功能等方面的重要作用而有望成為新一代治療2型糖尿病的藥物。本文介紹了ABHD6的作用機制,根據(jù)其結(jié)構(gòu)特點對此類抑制劑的最新研究進展進行綜述,并對其構(gòu)效關(guān)系進行分析。
[Abstract]:Type 2 diabetes mellitus (T2DM) is characterized by disorder of glucose and lipid metabolism and chronic damage of multiple organs. 偽 / 尾 hydrolase domain 6 (偽 / 尾 hydrolase domain-6 ABHD6) negatively regulates the release of insulin by hydrolyzing monoacylglycerol. Small molecule ABHD6 inhibitors are expected to be a new generation of drugs for type 2 diabetes because of their important roles in enhancing insulin sensitivity and improving fat function. In this paper, the mechanism of ABHD6 is introduced, the latest research progress of ABHD6 is reviewed according to its structural characteristics, and its structure-activity relationship is analyzed.
【作者單位】： 中國藥科大學(xué)新藥研究中心;
【分類號】：R977.15
，

本文編號：2131004